Market Cap
$212.0M
FHTX
Foghorn Therapeutics Inc.
$2.13 ▼ -27.05%
Prev close $2.92Market cap$212.0M
ConsensusStrong Buy
12-mo target$7.33 (+244.3%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10)15 New Institutional Positions4 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on FHTX right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (94%)
Inst. Holders
50 funds
Inst. Value
$90.3M
Inst. Activity
15 buys / 4 sells
Social Sentiment
50° Neutral
SEC Reports
3
Press Releases
1
Price chart 30d -58.8%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 trading_halt
Aug 6, 2026 SEC Halt Resumed: FHTX — trading resumed after T3 (News and Resumption Times)
Halted 2026-10-01T10:55:00.000Z | Resumed 2026-10-01T11:30:00.000Z
Foghorn Therapeutics reported Q2 2026 financial results with a net loss of $7.2M, significantly narrower than the $17.9M
8-K — Impact 5/10
Jun 30, 2026 Inst.
Qube Research & Technologies — DOUBLED
203,296 shares ($992.1K)
Jun 30, 2026 Inst.
PANAGORA ASSET MANAGEMENT INC — ADD
175,406 shares ($856.0K)
Jun 24, 2026 Insider
PARSHALL B LYNNE was granted 28,000 shares
Director @ $4.08 ($114.2K)
Jun 24, 2026 Insider
GILL SIMBA was granted 28,000 shares
Director @ $4.08 ($114.2K)
Jun 24, 2026 Insider
May 7, 2026 SEC SMITH IAN F was granted 28,000 shares
Director @ $4.08 ($114.2K)
Foghorn Therapeutics reported Q1 2026 collaboration revenue of $3.3M (down from $6.0M YoY), net loss of $19.9M (vs $18.8
8-K — Impact 3/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
94% rate it Buy or better · 16 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 2, 2026 | Wedbush | DOWNGRADE | Neutral | 57% |
| Oct 2, 2026 | TD Cowen | DOWNGRADE | Hold | 56% |
| Oct 2, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Oct 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Oct 2, 2026 | BTIG | DOWNGRADE | Neutral | 53% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Aug 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Jul 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Jun 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% |
Price targets
Where 6 covering analysts think FHTX trades over the next 12 months.
$7.33 +244.3% upside Strong Buy
Current$2.13 Low$5.00 Median$5.00 High$14.00 6 analysts
$5.00$14.00
Analyst rating Buy· 1.6/5 as of Oct 2, 2026
Social media sentiment mood -33.3%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
3 SEC filing reports analyzed · 1 bullish, 0 bearish, 1 mixed, 1 neutral · avg impact 5.0/10.Plus 1 press releases.
MIXED8-K5/10
Foghorn Therapeutics reported Q2 2026 financial results with a net loss of $7.2M, significantly narr
Aug 6, 2026
NEUTRAL8-K3/10
Foghorn Therapeutics reported Q1 2026 collaboration revenue of $3.3M (down from $6.0M YoY), net loss
May 7, 2026
BULLISH8-K7/10
Foghorn Therapeutics presented new preclinical data at AACR 2026 showing promising results across it
Apr 21, 2026
BULLISH7/10
Foghorn Therapeutics presented new preclinical data at AACR 2026 showing complete and durable tumor
Apr 21, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
trading_halt
Halt Resumed: FHTX — trading resumed after T3 (News and Resumption Times)
Halted 2026-10-01T10:55:00.000Z | Resumed 2026-10-01T11:30:00.000Z
Oct 1, 2026
trading_halt
Trading Halt: FHTX — T1 (News Pending)
Foghorn Therapeutics Cmn | Market: NASDAQ | Code: T1 — News Pending
Oct 1, 2026
trading_halt
Trading Halt: FHTX — T3 (News and Resumption Times)
Foghorn Therapeutics Cmn | Market: NASDAQ | Code: T3 — News and Resumption Times
Aug 20, 2026
short_volume
Short Volume: FHTX — 62.0% short (0.5M / 0.8M)
Short: 479,153 | Exempt: 25,191 | TRF Vol: 773,247 | Short Ratio: 62.0% | Off-exchange volume (dark pool + OTC)
Aug 11, 2026
earnings_calendar
FHTX Q2 2026 Earnings Before Market Open — 2026-08-11
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.25 | $-0.41–$-0.15 | -0.6% | -9.3% | 4↑ 1↓ | $0.0B | 7 |
| Next Q | $-0.25 | $-0.33–$-0.16 | 31.6% | -14.4% | 4↑ 1↓ | $0.0B | 7 |
| Current FY | $-0.93 | $-1.22–$-0.70 | 23.3% | -5.7% | 7↑ 0↓ | $0.0B | 8 |
| Next FY | $-1.03 | $-2.01–$-0.67 | -10.9% | +6.0% | 6↑ 1↓ | $0.0B | 8 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.251 | — |
| 7d ago | $-0.230 | -0.021 |
| 30d ago | $-0.230 | -0.021 |
| 60d ago | $-0.240 | -0.011 |
| 90d ago | $-0.240 | -0.011 |
Institutional ownership
Which big funds own FHTX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $90.3M total value (18,504,323 shares) as of 2026-Q2. Top holders: FMR, BlackRock,, RAYMOND. Net buying activity: 15 institutions added/increased vs 4 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 5,705,958 | $27.8M | 30.8% | — |
| BlackRock, Inc. | 2,626,832 | $12.8M | 14.2% | — |
| RAYMOND JAMES FINANCIAL INC | 2,489,978 | $12.2M | 13.5% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,494,611 | $7.3M | 8.1% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 910,866 | $4.4M | 4.9% | — |
| STATE STREET CORP | 697,469 | $3.4M | 3.8% | — |
| AMERIPRISE FINANCIAL INC | 558,685 | $2.7M | 3.0% | TRIM -26.1% |
| RENAISSANCE TECHNOLOGIES LLC | 377,936 | $1.8M | 2.0% | ADD +36.5% |
| Candriam S.C.A. | 313,765 | $1.5M | 1.7% | — |
| NORTHERN TRUST CORP | 309,775 | $1.5M | 1.7% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Qube Research & Technologies Ltd | DOUBLED | 81,278 | 203,296 | +150.1% | $992.1K |
| PANAGORA ASSET MANAGEMENT INC | ADD | 115,063 | 175,406 | +52.4% | $856.0K |
| Squarepoint Ops LLC | ADD | 103,743 | 130,346 | +25.6% | $636.1K |
| Nuveen, LLC | ADD | 50,378 | 65,039 | +29.1% | $317.4K |
| MILLENNIUM MANAGEMENT LLC | ADD | 29,552 | 53,509 | +81.1% | $261.1K |
| DEUTSCHE BANK AG\ | ADD | 27,421 | 36,537 | +33.2% | $178.3K |
| Jump Financial, LLC | DOUBLED | 13,740 | 36,383 | +164.8% | $177.5K |
| WELLS FARGO & COMPANY/MN | DOUBLED | 14,741 | 35,301 | +139.5% | $172.3K |
| BANK OF AMERICA CORP /DE/ | TRIM | 60,100 | 26,103 | -56.6% | $127.4K |
| CITIGROUP INC | DOUBLED | 3,415 | 18,544 | +443.0% | $90.5K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
16 insiders, 18 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 24, 2026 | PARSHALL B LYNNE | Director | AWARD | 28,000 | $4.08 | $114.2K |
| Jun 24, 2026 | GILL SIMBA | Director | AWARD | 28,000 | $4.08 | $114.2K |
| Jun 24, 2026 | SMITH IAN F | Director | AWARD | 28,000 | $4.08 | $114.2K |
| Jun 24, 2026 | Cole Douglas G. | Director | AWARD | 28,000 | $4.08 | $114.2K |
| Jun 24, 2026 | Biller Scott | Director | AWARD | 28,000 | $4.08 | $114.2K |
| Jun 24, 2026 | Mendelsohn Michael | Director | AWARD | 28,000 | $4.08 | $114.2K |
| Jun 24, 2026 | Gallagher Neil | Director | AWARD | 28,000 | $4.08 | $114.2K |
| Jun 24, 2026 | Lynch Thomas J. Jr. | Director | AWARD | 28,000 | $4.08 | $114.2K |
| Jun 24, 2026 | Duty Stuart | Director | AWARD | 28,000 | $4.08 | $114.2K |
| Apr 10, 2026 | GOTTSCHALK ADRIAN | Chief Executive Officer | GIFT | 59,208 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for FHTX.
Shares short
1,992,972
Settlement Sep 15, 2026
Change vs prior
+1.2%
Semi-monthly cycle
Days to cover
5.2
At avg daily volume
Of shares outstanding
≈3.4%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Oct 1, 2026 | T1 | News Pending | Not resumed |
| Oct 1, 2026 | T3 | Resumption Scheduled | Resumed |
All FHTX filing & press-release reports (4)
- 8-K reportAug 6, 2026
- 8-K reportMay 7, 2026
- 8-K reportApr 21, 2026
- PRESS-RELEASE reportApr 21, 2026